TY - JOUR T1 - Impact of mass testing during an epidemic rebound of SARS-CoV-2: A modelling study JF - medRxiv DO - 10.1101/2020.12.08.20246009 SP - 2020.12.08.20246009 AU - Paolo Bosetti AU - Cécile Tran Kiem AU - Yazdan Yazdanpanah AU - Arnaud Fontanet AU - Bruno Lina AU - Vittoria Colizza AU - Simon Cauchemez Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/13/2020.12.08.20246009.abstract N2 - We used a mathematical model to evaluate the impact of mass testing in the control of SARS-CoV-2. Conditions required to control a quickly growing epidemic with mass testing appear impossible to achieve. Mass testing should therefore not be seen as a silver bullet that will ensure other control measures can be removed. Even under a set of optimistic assumptions, this strategy is most relevant when epidemic growth remains limited, thanks to a combination of interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge financial support from the Investissement d'Avenir program, the Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases program (grant ANR-10-LABX-62-IBEID), Sant&eacute Publique France, the INCEPTION project (PIA/ANR-16-CONV-0005), and the European Union's Horizon 2020 research and innovation program under grants 101003589 (RECOVER).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo data referred in the manuscript. ER -